Through an exclusive partnership between the Healius Pathology Network and Proteomics International, clinicians can access innovative proteomics based tests designed to support earlier risk assessment, more informed clinical decision-making and personalised patient care.
Developed in Australia and available exclusively through the Healius Pathology Network, the Proteomics portfolio represents a new generation of biomarker based diagnostics that complement existing pathology testing and clinical assessment.
Proteomics is the study of proteins and how they change in response to biological processes and disease. Unlike genetic testing, which assesses inherited risk, proteomics measures proteins circulating in the body at the time of testing and may provide insight into current biological activity and future disease risk.
As precision medicine continues to evolve, proteomics based testing has the potential to support:
Future risk assessment for patients with type 1 and type 2 diabetes.
The Diabetes-related Kidney Disease Test assesses future risk of chronic kidney disease in adults with type 2 diabetes and can provide insight into future kidney disease risk up to four years before symptoms may appear.
Suitable for patients who:
Supporting risk assessment in patients with chronic reflux.
The Oesophageal Cancer Risk Test is a blood-based assessment designed to support evaluation of oesophageal adenocarcinoma risk in appropriate patients presenting with chronic reflux symptoms and recognised risk factors.
Suitable for patients who:
